| Second Quarter Report 2010 |
|
June 30, 2010
Dear Shareholder,
Total revenue for the second quarter 2010 was $14,590 compared to $5,398 for the 2009 second quarter. We continue to add new customers as well as increasing sales volume from established accounts. EndoPrep™, BioDtech, Inc.'s patent pending technology now accounts for 30% of total revenue.
We have introduced our new technology EndoHep™ which is designed to accurately determine endotoxin in the presence of Heparin, a widely used clinical anticoagulant. We have also filed a provisional patent application with the US patent office for this technology.
Sincerely,
Michael G. Pepe, Ph.D. Chairman, President and CEO
|
